SCHEDULE 13G/A: Commodore Capital Discloses 7.2% Passive Stake in Bright Minds Biosciences Inc.
Beneficial Ownership Report
Commodore Capital LP and Commodore Capital Master LP have reported a passive beneficial ownership of 7.2% in Bright Minds Biosciences Inc., totaling 500,000 common shares as of December 31, 2024.
Summary
- Commodore Capital LP, a Delaware limited partnership, and Commodore Capital Master LP, a Cayman Islands exempted limited partnership, have filed an Amendment No. 1 to Schedule 13G.
- The filing reports beneficial ownership of 500,000 Common Shares, without par value, of Bright Minds Biosciences Inc.
- This ownership represents 7.2% of the Issuer's outstanding Common Shares, based on 6,988,989 shares reported as issued and outstanding as of December 20, 2024.
- Commodore Capital LP serves as the investment manager to Commodore Capital Master LP.
- Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP and exercise investment discretion over these securities.
- The securities were acquired and are held for investment purposes and not with the intent of changing or influencing the control of the issuer, indicating a passive investment strategy.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing a passive beneficial ownership stake, which does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- The disclosure of a significant 7.2% stake by an institutional investor like Commodore Capital may signal investor confidence in Bright Minds Biosciences Inc.
Future Outlook
The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment firm in a publicly traded company. It does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor's stake may influence market perception and investor confidence in Bright Minds Biosciences Inc.
Key Dates
| Date | Description |
|---|---|
| 12/20/2024 | Date as of which 6,988,989 Common Shares were reported as issued and outstanding in the Issuer's Annual Report on Form 20-F. |
| 12/31/2024 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 02/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Bright Minds Biosciences Inc., Commodore Capital LP, Commodore Capital Master LP, Schedule 13G, Beneficial Ownership, Common Shares, Passive Investment, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.